Table 1.

Data included in this study.

Reference	Publication date	First and last author	Journal	Tumor type	Patients	Peptides tested	T cell responses	Test method	Peptide lengths
(16)	2013–05	Robbins et al. and Rosenberg	Nat Med	SKCM	3	227	10	ELISPOT	9–10
(17)	2013–11	Van Roij et al. and Schumacher	J Clin Oncol	SKCM	1	–	1	FLT	9
(18)	2014–03	Wick et al. and Nelson	Clin Cancer Res	HGSC	3	109	1	ELISPOT	8–11
(19)	2014–06	Rajasagi et al. and Wu	Blood	CLL	2	48	3	ELISPOT	9–10
(20)	2014–07	Lu et al. and Robbins	Clin Cancer Res	SKCM	2	10	2	ELISA	8–11
(1)	2014–12	Snyder et al. and Chan	N Engl J Med	SKCM	1	–	1	ICS	9
(2)	2015–04	Rizvi et al. and Chan	Science	NSCLC	1	–	1	FLT	9
(21)	2015–10	Cohen et al. Robbins	J Clin Invest	SKCM	8	427	9	FLT	9–10
(22)	2016–01	Kalaora et al. and Samuels	Oncotarget	SKCM	1	2	1	ICS	9, 11
(23)	2016–03	McGranahan et al. and Swanton	Science	NSCLC	2a	642a	3/8a	FLT/BLM	9–11
(24)	2016–05	Strønen et al. and Schumacher	Science	SKCM	4	56	11	FLT	9–11
(25)	2016–05	Bassani-Sternberg et al. and Krackhardt	Nature Commun	SKCM	1	8	2	MS-FLT	8–10, 12
(26)	2016–08	Bentzen et al. and Hadrup	Nat Biotechnol	NSCLC	2a	703a	9a	BLM	9–11
	Total	13		4	30	1,874	53	5	5

1,874 unique tested peptides, 1,948 peptide-HLA combinations, from 27 HLA alleles.

FLT, fluorescently labeled tetramers; BLM, DNA barcode-labeled multimers; ICS, intracellular cytokine staining; MS, mass spectrometry; SKCM, skin cutaneous melanoma; NSCLC, non-small cell lung cancer; CLL, chronic lymphocytic leukemia; HGSC, ovarian high grade serous carcinoma.

^aPeptides and patient overlap between studies.